Furthermore, IL-2 has been the subject of numerous clinical trials in cancer immunotherapy, and recombinant IL-2 has already demonstrated efficacy in stimulating antitumor immunity in several malignancies, including melanoma, renal cell carcinoma and cervical cancer [17, 18]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.